Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

TAF proteins may serve as potential targets to fight ovarian cancer

In the complex genomic and molecular conspiracy that gives rise to ovarian cancer, what if researchers have been missing a whole set of suspects because they've been hiding in plain sight?

17 Mar 2014

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).

11 Mar 2014

Sugars attached to proteins can be used to detect ovarian cancer, say researchers

The hunt is on to find biomarkers that detect cancer, but it's a challenging process. Early successes often are followed by heartbreaking failures. But now, researchers at UC Davis have verified that glycans (sugars attached to proteins) can be used to detect ovarian cancer. The study was published online in the journal Cancer Epidemiology, Biomarkers & Prevention.

11 Mar 2014

Glycoprofiling test could halve number of false-positives in diagnosis of ovarian cancer

11 Mar 2014

New sugar-test may reduce false-positive ovarian cancer screening tests

The world's most widespread test for ovarian cancer reports false-positives in 94 of 100 diagnosed cases. Now, chemists at the University of Copenhagen working with clinical researchers at University College London have developed a method able to halve the number of false-positives. When fully developed, the new test will spare a significant number of women from unnecessary worry and further testing. Furthermore, global health care providers stand to save substantial sums - just by including a test on a certain sugar molecule in tandem with the currently prevailing diagnostic test.

10 Mar 2014

Novel cancer immunotherapy approach may provide new weapon against most deadly tumors

A novel approach to cancer immunotherapy - strategies designed to induce the immune system to attack cancer cells - may provide a new and cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma.

6 Mar 2014

Washington Hospital recognized as 'Baby-Friendly Hospital'

Washington Hospital has earned the distinction as a "Baby-Friendly Hospital" from the Baby-Friendly Hospital Initiative, a global program launched by the World Health Organization and the United Nations Children's Fund. The designation recognizes hospitals and birthing centers that offer an optimal level of care for infant feeding and mother/baby bonding. Fewer than 175 hospitals in the U.S. are "Baby-Friendly."

6 Mar 2014

Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced solid tumors, including one patient with mesothelioma. The Phase 1 study assessed the safety and pharmacokinetics of single agent VS-6063.

5 Mar 2014

Randomized trial of bevacizumab for glioblastoma shows disappointing results

"The results of this study are counter to most expectations," said Dr. Brachman, Director of Radiation Oncology at Barrow and St. Joseph's. "Bevacizumab had been shown in earlier studies to be an effective drug in the treatment of patients with recurrent disease. But, on newly diagnosed patients, it did not, in fact, prolong survival."

3 Mar 2014

Survival rates for bladder cancer in UK are falling, confirms new study

Of the top 10 cancers in the UK, bladder cancer is only one where survival rates have been shown to be getting worse. New figures published this month in the Journal of Clinical Urology confirm in a study of cases of bladder cancer in England over a 19 year period (from 1990 until 2009) that survival rates here in the UK are falling and are worse than in than in other European countries with similar incidence rates.

27 Feb 2014

Caffeine-based compound with small amount of gold could be used as anticancer agent

The side effects of ingesting too much caffeine - restlessness, increased heart rate, having trouble sleeping - are well known, but recent research has shown that the stimulant also has a good side. It can kill cancer cells.

26 Feb 2014

Study highlights the importance of personalized medicine for treating cancer

If a driver is traveling to New York City, I-95 might be their route of choice. But they could also take I-78, I-87 or any number of alternate routes. Most cancers begin similarly, with many possible routes to the same disease. A new study found evidence that assessing the route to cancer on a case-by-case basis might make more sense than basing a patient's cancer treatment on commonly disrupted genes and pathways.

26 Feb 2014

Preventive oophorectomy reduces risks of ovarian, breast cancers in women with BRCA mutation

Women who carry a BRCA gene mutation and opt for a preventive oophorectomy, or ovary removal surgery, have a 77 per cent lower risk of death than those who do not, according to a new study led by Women's College Hospital's Amy Finch and Dr. Steven Narod.

26 Feb 2014

Study: Women with BRCA1 mutations should have preventive ovarian surgery by age 35

The findings of a large international prospective study published in the Journal of Clinical Oncology suggest for the first time that women with BRCA1 mutations should have preventive ovarian surgery (prophylactic oophorectomy) by age 35, as waiting until a later age appears to increase the risk of ovarian cancer before or at the time of the preventive surgery.

25 Feb 2014

Tel Aviv University scientists target drug-resistant ovarian tumors with nanotechnology

Ovarian cancer accounts for more deaths of American women than any other cancer of the female reproductive system. According to the American Cancer Society, one in 72 American women will be diagnosed with ovarian cancer, and one in 100 will ultimately die of the condition.

24 Feb 2014

Idiopathic pulmonary fibrosis could soon be diagnosed without the need for surgical lung biopsy

People who have suspected idiopathic pulmonary fibrosis without typical patterns on high resolution computed tomography scans could in future be spared the substantial risks of lung biopsy and be given a confident diagnosis of IPF based on clinical and radiological findings alone, according to new research published in The Lancet Respiratory Medicine.

20 Feb 2014

New biologic drug to prevent growth of ovarian cancer cells

Researchers at Women & Infants Hospital of Rhode Island have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. This would improve treatment and survival rates for some women.

20 Feb 2014

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

California Stem Cell, Inc. (CSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer.

19 Feb 2014

Matching the right tumor with the right drug

There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.

19 Feb 2014

Commonly-used HIV drug kills HPV that leads to cervical cancer

A commonly-used HIV drug has been shown to kill-off the human papilloma virus (HPV) that leads to cervical cancer in a world-first clinical trial led by The University of Manchester with Kenyatta National Hospital in Nairobi.

17 Feb 2014

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

TAF proteins may serve as potential targets to fight ovarian cancer

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Sugars attached to proteins can be used to detect ovarian cancer, say researchers

Glycoprofiling test could halve number of false-positives in diagnosis of ovarian cancer

New sugar-test may reduce false-positive ovarian cancer screening tests

Novel cancer immunotherapy approach may provide new weapon against most deadly tumors

Washington Hospital recognized as 'Baby-Friendly Hospital'

Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Randomized trial of bevacizumab for glioblastoma shows disappointing results

Survival rates for bladder cancer in UK are falling, confirms new study

Caffeine-based compound with small amount of gold could be used as anticancer agent

Study highlights the importance of personalized medicine for treating cancer

Preventive oophorectomy reduces risks of ovarian, breast cancers in women with BRCA mutation

Study: Women with BRCA1 mutations should have preventive ovarian surgery by age 35

Tel Aviv University scientists target drug-resistant ovarian tumors with nanotechnology

Idiopathic pulmonary fibrosis could soon be diagnosed without the need for surgical lung biopsy

New biologic drug to prevent growth of ovarian cancer cells

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

Matching the right tumor with the right drug

Commonly-used HIV drug kills HPV that leads to cervical cancer

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in